Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

The Evolving Landscape of Autoantigen Discovery and Characterization in Type 1 Diabetes.

Purcell AW, Sechi S, DiLorenzo TP.

Diabetes. 2019 May;68(5):879-886. doi: 10.2337/dbi18-0066.

PMID:
31010879
2.

HLA-B*39:06 Efficiently Mediates Type 1 Diabetes in a Mouse Model Incorporating Reduced Thymic Insulin Expression.

Schloss J, Ali R, Racine JJ, Chapman HD, Serreze DV, DiLorenzo TP.

J Immunol. 2018 May 15;200(10):3353-3363. doi: 10.4049/jimmunol.1701652. Epub 2018 Apr 9.

3.

Improved Murine MHC-Deficient HLA Transgenic NOD Mouse Models for Type 1 Diabetes Therapy Development.

Racine JJ, Stewart I, Ratiu J, Christianson G, Lowell E, Helm K, Allocco J, Maser RS, Chen YG, Lutz CM, Roopenian D, Schloss J, DiLorenzo TP, Serreze DV.

Diabetes. 2018 May;67(5):923-935. doi: 10.2337/db17-1467. Epub 2018 Feb 22.

4.

Bridging Mice to Men: Using HLA Transgenic Mice to Enhance the Future Prediction and Prevention of Autoimmune Type 1 Diabetes in Humans.

Serreze DV, Niens M, Kulik J, DiLorenzo TP.

Methods Mol Biol. 2016;1438:137-51. doi: 10.1007/978-1-4939-3661-8_9. Review.

PMID:
27150089
5.

Genetically modified human CD4(+) T cells can be evaluated in vivo without lethal graft-versus-host disease.

Ali R, Babad J, Follenzi A, Gebe JA, Brehm MA, Nepom GT, Shultz LD, Greiner DL, DiLorenzo TP.

Immunology. 2016 Aug;148(4):339-51. doi: 10.1111/imm.12613.

6.

An HLA-Transgenic Mouse Model of Type 1 Diabetes That Incorporates the Reduced but Not Abolished Thymic Insulin Expression Seen in Patients.

Babad J, Ali R, Schloss J, DiLorenzo TP.

J Diabetes Res. 2016;2016:7959060. doi: 10.1155/2016/7959060. Epub 2015 Dec 28.

7.

Characterization of the peptide binding specificity of the HLA class I alleles B*38:01 and B*39:06.

Sidney J, Schloss J, Moore C, Lindvall M, Wriston A, Hunt DF, Shabanowitz J, DiLorenzo TP, Sette A.

Immunogenetics. 2016 Mar;68(3):231-6. doi: 10.1007/s00251-015-0898-2. Epub 2016 Jan 11.

8.

Delivery of siRNAs to Dendritic Cells Using DEC205-Targeted Lipid Nanoparticles to Inhibit Immune Responses.

Katakowski JA, Mukherjee G, Wilner SE, Maier KE, Harrison MT, DiLorenzo TP, Levy M, Palliser D.

Mol Ther. 2016 Feb;24(1):146-55. doi: 10.1038/mt.2015.175. Epub 2015 Sep 28.

9.

Glucagon-reactive islet-infiltrating CD8 T cells in NOD mice.

Mukherjee G, Chaparro RJ, Schloss J, Smith C, Bando CD, DiLorenzo TP.

Immunology. 2015 Apr;144(4):631-40. doi: 10.1111/imm.12415.

10.

Generation of β cell-specific human cytotoxic T cells by lentiviral transduction and their survival in immunodeficient human leucocyte antigen-transgenic mice.

Babad J, Mukherjee G, Follenzi A, Ali R, Roep BO, Shultz LD, Santamaria P, Yang OO, Goldstein H, Greiner DL, DiLorenzo TP.

Clin Exp Immunol. 2015 Mar;179(3):398-413. doi: 10.1111/cei.12465.

11.

Compensatory mechanisms allow undersized anchor-deficient class I MHC ligands to mediate pathogenic autoreactive T cell responses.

Lamont D, Mukherjee G, Kumar PR, Samanta D, McPhee CG, Kay TW, Almo SC, DiLorenzo TP, Serreze DV.

J Immunol. 2014 Sep 1;193(5):2135-46. doi: 10.4049/jimmunol.1400997. Epub 2014 Jul 25.

12.

DEC-205-mediated antigen targeting to steady-state dendritic cells induces deletion of diabetogenic CD8⁺ T cells independently of PD-1 and PD-L1.

Mukherjee G, Geliebter A, Babad J, Santamaria P, Serreze DV, Freeman GJ, Tarbell KV, Sharpe A, DiLorenzo TP.

Int Immunol. 2013 Nov;25(11):651-60. doi: 10.1093/intimm/dxt031. Epub 2013 Sep 10.

13.

Beyond HLA-A*0201: new HLA-transgenic nonobese diabetic mouse models of type 1 diabetes identify the insulin C-peptide as a rich source of CD8+ T cell epitopes.

Antal Z, Baker JC, Smith C, Jarchum I, Babad J, Mukherjee G, Yang Y, Sidney J, Sette A, Santamaria P, DiLorenzo TP.

J Immunol. 2012 Jun 1;188(11):5766-75. doi: 10.4049/jimmunol.1102930. Epub 2012 Apr 25.

14.

Multiple antigens versus single major antigen in type 1 diabetes: arguing for multiple antigens.

DiLorenzo TP.

Diabetes Metab Res Rev. 2011 Nov;27(8):778-83. doi: 10.1002/dmrr.1251. Review.

PMID:
22069259
15.

Structural and functional characterization of a single-chain peptide-MHC molecule that modulates both naive and activated CD8+ T cells.

Samanta D, Mukherjee G, Ramagopal UA, Chaparro RJ, Nathenson SG, DiLorenzo TP, Almo SC.

Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):13682-7. doi: 10.1073/pnas.1110971108. Epub 2011 Aug 8.

16.

T-cell autoantigens in the non-obese diabetic mouse model of autoimmune diabetes.

Babad J, Geliebter A, DiLorenzo TP.

Immunology. 2010 Dec;131(4):459-65. doi: 10.1111/j.1365-2567.2010.03362.x. Epub 2010 Oct 13. Review.

17.

An update on the use of NOD mice to study autoimmune (Type 1) diabetes.

Chaparro RJ, Dilorenzo TP.

Expert Rev Clin Immunol. 2010 Nov;6(6):939-55. doi: 10.1586/eci.10.68.

18.

The immunotherapeutic potential of dendritic cells in type 1 diabetes.

Mukherjee G, Dilorenzo TP.

Clin Exp Immunol. 2010 Aug;161(2):197-207. doi: 10.1111/j.1365-2249.2010.04157.x. Epub 2010 May 10. Review.

19.

Autoimmunity. The benefit of self-control.

Santambrogio L, DiLorenzo TP.

Immunol Cell Biol. 2010 Jul;88(5):513-4. doi: 10.1038/icb.2010.59. Epub 2010 Apr 20. No abstract available.

PMID:
20404836
20.

Predominant occupation of the class I MHC molecule H-2Kwm7 with a single self-peptide suggests a mechanism for its diabetes-protective effect.

Brims DR, Qian J, Jarchum I, Mikesh L, Palmieri E, Ramagopal UA, Malashkevich VN, Chaparro RJ, Lund T, Hattori M, Shabanowitz J, Hunt DF, Nathenson SG, Almo SC, Dilorenzo TP.

Int Immunol. 2010 Mar;22(3):191-203. doi: 10.1093/intimm/dxp127. Epub 2010 Jan 21.

21.

Bridging mice to men: using HLA transgenic mice to enhance the future prediction and prevention of autoimmune type 1 diabetes in humans.

Serreze DV, Niens M, Kulik J, Dilorenzo TP.

Methods Mol Biol. 2010;602:119-34. doi: 10.1007/978-1-60761-058-8_8.

PMID:
20012396
22.

Ins2 deficiency augments spontaneous HLA-A*0201-restricted T cell responses to insulin.

Jarchum I, DiLorenzo TP.

J Immunol. 2010 Jan 15;184(2):658-65. doi: 10.4049/jimmunol.0903414. Epub 2009 Dec 4.

23.

HLA class I supertypes in type 1 diabetic children in an urban children's hospital.

Antal Z, Jarchum I, DiLorenzo TP.

Ann N Y Acad Sci. 2008 Dec;1150:86-9. doi: 10.1196/annals.1447.005.

24.

Lentivectors encoding immunosuppressive proteins genetically engineer pancreatic beta-cells to correct diabetes in allogeneic mice.

Kojaoghlanian T, Joseph A, Follenzi A, Zheng JH, Leiser M, Fleischer N, Horwitz MS, DiLorenzo TP, Goldstein H.

Gene Ther. 2009 Mar;16(3):340-8. doi: 10.1038/gt.2008.172. Epub 2008 Dec 25.

25.

Efficient culture of CD8(+) T cells from the islets of NOD mice and their use for the study of autoreactive specificities.

Jarchum I, Takaki T, DiLorenzo TP.

J Immunol Methods. 2008 Nov 30;339(1):66-73. doi: 10.1016/j.jim.2008.08.007. Epub 2008 Sep 7.

26.

Rapid identification of MHC class I-restricted antigens relevant to autoimmune diabetes using retrogenic T cells.

Chaparro RJ, Burton AR, Serreze DV, Vignali DA, DiLorenzo TP.

J Immunol Methods. 2008 Jun 1;335(1-2):106-15. doi: 10.1016/j.jim.2008.03.007. Epub 2008 Apr 8.

27.

Selective delivery of beta cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8+ T cells in NOD mice.

Mukhopadhaya A, Hanafusa T, Jarchum I, Chen YG, Iwai Y, Serreze DV, Steinman RM, Tarbell KV, DiLorenzo TP.

Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6374-9. doi: 10.1073/pnas.0802644105. Epub 2008 Apr 22.

28.

Identification of novel IGRP epitopes targeted in type 1 diabetes patients.

Jarchum I, Nichol L, Trucco M, Santamaria P, DiLorenzo TP.

Clin Immunol. 2008 Jun;127(3):359-65. doi: 10.1016/j.clim.2008.01.015. Epub 2008 Mar 20.

29.

Structural genomics of protein phosphatases.

Almo SC, Bonanno JB, Sauder JM, Emtage S, Dilorenzo TP, Malashkevich V, Wasserman SR, Swaminathan S, Eswaramoorthy S, Agarwal R, Kumaran D, Madegowda M, Ragumani S, Patskovsky Y, Alvarado J, Ramagopal UA, Faber-Barata J, Chance MR, Sali A, Fiser A, Zhang ZY, Lawrence DS, Burley SK.

J Struct Funct Genomics. 2007 Sep;8(2-3):121-40. Epub 2007 Dec 5. Review.

30.

Assembly and structural properties of glucocorticoid-induced TNF receptor ligand: Implications for function.

Chattopadhyay K, Ramagopal UA, Mukhopadhaya A, Malashkevich VN, Dilorenzo TP, Brenowitz M, Nathenson SG, Almo SC.

Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19452-7. Epub 2007 Nov 26.

31.

In vivo cytotoxicity of insulin-specific CD8+ T-cells in HLA-A*0201 transgenic NOD mice.

Jarchum I, Baker JC, Yamada T, Takaki T, Marron MP, Serreze DV, DiLorenzo TP.

Diabetes. 2007 Oct;56(10):2551-60. Epub 2007 Jul 9.

32.

"Humanized" HLA transgenic NOD mice to identify pancreatic beta cell autoantigens of potential clinical relevance to type 1 diabetes.

Serreze DV, Marron MP, Dilorenzo TP.

Ann N Y Acad Sci. 2007 Apr;1103:103-11. Epub 2007 Mar 21.

PMID:
17376821
33.

T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface.

Cao E, Zang X, Ramagopal UA, Mukhopadhaya A, Fedorov A, Fedorov E, Zencheck WD, Lary JW, Cole JL, Deng H, Xiao H, Dilorenzo TP, Allison JP, Nathenson SG, Almo SC.

Immunity. 2007 Mar;26(3):311-21.

34.

Improved outcomes in NOD mice treated with a novel Th2 cytokine-biasing NKT cell activator.

Forestier C, Takaki T, Molano A, Im JS, Baine I, Jerud ES, Illarionov P, Ndonye R, Howell AR, Santamaria P, Besra GS, Dilorenzo TP, Porcelli SA.

J Immunol. 2007 Feb 1;178(3):1415-25.

35.

HLA-A*0201-restricted T cells from humanized NOD mice recognize autoantigens of potential clinical relevance to type 1 diabetes.

Takaki T, Marron MP, Mathews CE, Guttmann ST, Bottino R, Trucco M, DiLorenzo TP, Serreze DV.

J Immunol. 2006 Mar 1;176(5):3257-65.

37.

Developmental control of CD8 T cell-avidity maturation in autoimmune diabetes.

Han B, Serra P, Yamanouchi J, Amrani A, Elliott JF, Dickie P, Dilorenzo TP, Santamaria P.

J Clin Invest. 2005 Jul;115(7):1879-87. Epub 2005 Jun 2.

38.

The good turned ugly: immunopathogenic basis for diabetogenic CD8+ T cells in NOD mice.

DiLorenzo TP, Serreze DV.

Immunol Rev. 2005 Apr;204:250-63. Review. Erratum in: Immunol Rev. 2005 Aug;206:336.

PMID:
15790363
39.
40.

Requirement for both H-2Db and H-2Kd for the induction of diabetes by the promiscuous CD8+ T cell clonotype AI4.

Takaki T, Lieberman SM, Holl TM, Han B, Santamaria P, Serreze DV, DiLorenzo TP.

J Immunol. 2004 Aug 15;173(4):2530-41.

41.

MHC class II molecules play a role in the selection of autoreactive class I-restricted CD8 T cells that are essential contributors to type 1 diabetes development in nonobese diabetic mice.

Serreze DV, Holl TM, Marron MP, Graser RT, Johnson EA, Choisy-Rossi C, Slattery RM, Lieberman SM, DiLorenzo TP.

J Immunol. 2004 Jan 15;172(2):871-9.

42.

A comprehensive guide to antibody and T-cell responses in type 1 diabetes.

Lieberman SM, DiLorenzo TP.

Tissue Antigens. 2003 Nov;62(5):359-77. Review.

PMID:
14617043
43.

Identification of the beta cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes.

Lieberman SM, Evans AM, Han B, Takaki T, Vinnitskaya Y, Caldwell JA, Serreze DV, Shabanowitz J, Hunt DF, Nathenson SG, Santamaria P, DiLorenzo TP.

Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8384-8. Epub 2003 Jun 18.

44.

During the early prediabetic period in NOD mice, the pathogenic CD8(+) T-cell population comprises multiple antigenic specificities.

DiLorenzo TP, Lieberman SM, Takaki T, Honda S, Chapman HD, Santamaria P, Serreze DV, Nathenson SG.

Clin Immunol. 2002 Dec;105(3):332-41.

PMID:
12498815
45.

Immunobiological analysis of TCR single-chain transgenic mice reveals new possibilities for interaction between CDR3alpha and an antigenic peptide bound to MHC class I.

Zhang W, Honda S, Wang F, DiLorenzo TP, Kalergis AM, Ostrov DA, Nathenson SG.

J Immunol. 2001 Oct 15;167(8):4396-404.

46.

Hapten addition to an MHC class I-binding peptide causes substantial adjustments of the TCR structure of the responding CD8(+) T cells.

Honda S, Zhang W, Kalergis AM, DiLorenzo TP, Wang F, Nathenson SG.

J Immunol. 2001 Oct 15;167(8):4276-85.

47.

Autoreactive diabetogenic T-cells in NOD mice can efficiently expand from a greatly reduced precursor pool.

Serreze DV, Johnson EA, Chapman HD, Graser RT, Marron MP, DiLorenzo TP, Silveira P, Yoshimura Y, Nathenson SG, Joyce S.

Diabetes. 2001 Sep;50(9):1992-2000.

48.

Identification of a CD8 T cell that can independently mediate autoimmune diabetes development in the complete absence of CD4 T cell helper functions.

Graser RT, DiLorenzo TP, Wang F, Christianson GJ, Chapman HD, Roopenian DC, Nathenson SG, Serreze DV.

J Immunol. 2000 Apr 1;164(7):3913-8.

49.
50.

Supplemental Content

Loading ...
Support Center